Clinical Trial Update: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating second-line regimens PAD (bortezomib, doxorubicin, dexamethasone) or vincristine-doxorubicin-dexamethasone in multiple myeloma was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Adriamycin (doxorubicin)
• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)
• Vincristine (vincristine)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2014-03-21